Get the Stockscreener App
34.30
2.03%
-0.71
After Hours:
34.59
0.29
+0.85%
Moderna Inc stock is traded at $34.30, with a volume of 9.31M.
It is down -2.03% in the last 24 hours and up +7.46% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$35.01
Open:
$35.15
24h Volume:
9.31M
Relative Volume:
0.86
Market Cap:
$13.26B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-5.8935
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
+0.00%
1M Performance:
+7.46%
6M Performance:
-49.77%
1Y Performance:
-67.80%
1-Day Range:
$34.20
$38.12
1-Week Range:
$32.62
$38.12
52-Week Range:
$29.25
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
34.30 | 13.26B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Vestmark Advisory Solutions Inc. Has $292,000 Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Jones Financial Companies Lllp Has $617,000 Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Edgestream Partners L.P. Sells 19,869 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Citigroup Initiates Coverage of Moderna (BIT:1MRNA) with Neutral Recommendation - Nasdaq
Moderna explains how to stay protected from respiratory virus season - NTV
Moderna Stock: A Deep Dive Into Analyst Perspectives (10 Ratings) - Benzinga
Levi & Korsinsky Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024MRNA - ACCESS Newswire
mRNA Vaccines MarketPipeline Insights 2025-2032 - openPR
Citigroup starts coverage on Moderna, notes risky path to profitability - TradingView
Amundi Purchases 535,273 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Buys 168,975 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Reviewing BioCardia (NASDAQ:BCDA) & Moderna (NASDAQ:MRNA) - Defense World
AMF Tjanstepension AB Makes New $1.46 Million Investment in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Banco Santander S.A. - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Trims Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Stock Position Lifted by Charles Schwab Investment Management Inc. - MarketBeat
Moderna's Top Lawyer Compensation Jumps in Post-Pandemic Era - Bloomberg Law
As Moderna’s stock plunged, two top execs got big pay increases - The Business Journals
Moderna CLO Saw Comp Jump Fourfold To $17.3M - Law360
Moderna (NASDAQ:MRNA) Trading Down 6.3%What's Next? - MarketBeat
mRNA Vaccines & Therapeutics Market to Hit $ 503 Mn by 2032Key - openPR
3 Reasons MRNA is Risky and 1 Stock to Buy Instead - Financial Content
E Fund Management Co. Ltd. Increases Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
State of Michigan Retirement System Has $3.82 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Triples Legal Chief's Pay to Make Up for Plunge in Stock Price - Law.com
Moderna at Barclays Conference: Strategic Focus on Oncology and Vaccines - Investing.com
Investigation announced for Long-Term Investors in shares - openPR
mRNA Cancer Therapeutics Patent Landscape Report and - GlobeNewswire
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares - MarketBeat
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Where Will Vertex Pharmaceuticals Be in 10 Years? - The Motley Fool
US Bancorp DE Grows Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World
Oppenheimer & Co. Inc. Sells 27,823 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Shareholders that lost money on Moderna, Inc.(MRNA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
QRG Capital Management Inc. Reduces Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Investors who lost money on Moderna, Inc.(MRNA) should contact Levi & Korsinsky about pending Class ActionMRNA - ACCESS Newswire
German Court Rules Pfizer, BioNTech Infringed Moderna's COVID-19 Vaccine Patent - Law.com
Decoding Moderna's Options Activity: What's the Big Picture? - Benzinga
Moderna suffers setback in vaccine patent battle with Pfizer - The Business Journals
Candriam S.C.A. Sells 14,804 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap UpTime to Buy? - MarketBeat
Moderna (NasdaqGS:MRNA) Sees 15% Jump Despite Recent Revenue Challenges - Yahoo Finance
Why Moderna (MRNA) Stock Is Rallying Today - MSN
Okta, Moderna and MicroStrategy Are Among Top 10 Large-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? - Benzinga
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Mutual of America Capital Management LLC - Defense World
Top Biotech Stocks To Follow Today – March 7th - Defense World
3 CEOs Just Spent Millions Buying Their Beaten-Down Stock - Barron's
U.S. patent appeals panel delivers loss to Moderna in mRNA vaccine case - MSN
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):